NewsRx

Search our medical news database

Oscient Pharmaceuticals Corporation

Officials from Oscient Pharmaceuticals Corporation report latest developments

Published in Lab Law Weekly, May 25th, 2007

Officials from Oscient Pharmaceuticals Corporation report latest developments.

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Oscient Pharmaceuticals Corporation.

Report 1: Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) announced that it has commenced offers to exchange up to $185,600,000 aggregate principal amount of its new 3.50% Convertible Senior Notes due 2011 for up to all of the $152,750,000 aggregate principal amount of its currently outstanding 3 1/2% Senior Convertible Notes due 2011 and up to all of the $22,310,000 aggregate principal amount of its currently outstanding 5%...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook